Pevonedistat, a Neuronal Precursor Cell-Expressed Developmentally Down-Regulated Protein 8-Activating Enzyme Inhibitor, Is a Potent Inhibitor of Hepatitis B Virus.
Kazuma SekibaMotoyuki OtsukaMotoko OhnoMari YamagamiTakahiro KishikawaTakahiro SeimiyaTatsunori SuzukiEri TanakaRei IshibashiKazuyoshi FunatoKazuhiko KoikePublished in: Hepatology (Baltimore, Md.) (2019)
Hepatitis B virus (HBV) infection is a major health concern worldwide. To prevent HBV-related mortality, elimination of viral proteins is considered the ultimate goal of HBV treatment; however, currently available nucleos(t)ide analogs rarely achieve this goal, as viral transcription from episomal viral covalently closed circular DNA (cccDNA) is not prevented. HBV regulatory protein X was recently found to target the protein structural maintenance of chromosomes 5/6 (Smc5/6) for ubiquitination and degradation by DDB1-CUL4-ROC1 E3 ligase, resulting in enhanced viral transcription from cccDNA. This ubiquitin-dependent proteasomal pathway requires an additional ubiquitin-like protein for activation, neuronal precursor cell-expressed developmentally down-regulated protein 8 (NEDD8). Here, we show that pevonedistat, a NEDD8-activating enzyme inhibitor, works efficiently as an antiviral agent. Pevonedistat significantly restored Smc5/6 protein levels and suppressed viral transcription and protein production in the HBV minicircle system in in vitro HBV replication models and in human primary hepatocytes infected naturally with HBV. Conclusion: These results indicate that pevonedistat is a promising compound to treat chronic HBV infection.
Keyphrases
- hepatitis b virus
- liver failure
- sars cov
- transcription factor
- protein protein
- healthcare
- amino acid
- binding protein
- mental health
- stem cells
- public health
- cardiovascular disease
- signaling pathway
- endothelial cells
- type diabetes
- drug induced
- molecular docking
- cell free
- liver injury
- blood brain barrier
- circulating tumor
- bone marrow
- induced pluripotent stem cells